The endocannabinoid system was discovered because researchers wanted to know how THC works. Looking for its target in the body, they found receptors — and then discovered the body produces its own compounds that bind to them.
That sequence matters. The system is not there for cannabis. Cannabis happens to produce compounds that resemble molecules the body already uses.
The Three Components
The endocannabinoid system has three parts: receptors, the compounds that activate them, and the enzymes that build and break down those compounds.
Receptors
CB1 receptors are concentrated in the central nervous system — brain and spinal cord — with the highest densities in regions governing memory, mood, motor control, appetite and pain perception. They are among the most abundant receptors of their type in the brain.
THC’s intoxicating effects come from binding at CB1, and the distribution of those receptors is why the effects present the way they do. Notably, the brainstem regions controlling respiration have very few CB1 receptors, which is the pharmacological reason cannabis does not suppress breathing the way opioids can.
CB2 receptors are found mainly in immune tissue and peripheral organs. Activity here relates more to immune signalling and inflammation than to psychoactive effect.
Cannabinoids also interact with other targets — TRPV1, GPR55, serotonin and PPAR receptors among them — which is part of why CBD, which binds weakly at CB1, still has measurable effects.
Endocannabinoids
The body produces its own cannabinoids. Two are well characterised.
Anandamide (from the Sanskrit ananda, “bliss”) was the first identified. It binds at CB1 with moderate affinity and is broken down quickly by the enzyme FAAH.
2-AG is present at considerably higher concentrations and is a full agonist at both CB1 and CB2.
The crucial difference between endocannabinoids and plant cannabinoids is timing. Endocannabinoids are synthesised on demand, act locally, and are degraded within minutes. They are not stored and released like conventional neurotransmitters — they are made where and when they are needed, then removed.
Enzymes
FAAH breaks down anandamide; MAGL breaks down 2-AG. These are pharmacological targets in their own right — inhibiting them raises endocannabinoid levels without introducing an external compound, which is an active line of drug development independent of cannabis.
What the System Does
The endocannabinoid system operates largely as a regulator rather than a driver. Its main mechanism is retrograde signalling: a receiving neuron produces endocannabinoids that travel backwards across the synapse and reduce further transmitter release from the sending neuron.
Functionally it is a dimmer switch. It participates in maintaining balance across appetite and metabolism, pain perception, mood and stress response, sleep, immune function, memory, and motor control.
Because it modulates so many systems, disrupting it produces wide-ranging effects — and because it is a regulator rather than a primary driver, its effects are usually adjustments rather than switches.
Anandamide and THC Compared
Both act at CB1, and the differences explain a great deal.
Duration. Anandamide is degraded within minutes. THC persists for hours and is stored in fat tissue, releasing slowly over a much longer period.
Location. Endocannabinoids act precisely where they are produced. Inhaled or ingested THC reaches CB1 receptors throughout the body at once — including regions where the body was not signalling for any change.
Intensity. Endocannabinoid signalling is calibrated. THC arrives at whatever concentration was consumed.
That combination — longer, broader, less calibrated — is why THC produces effects the body’s own system does not, despite acting at the same receptor.
Why CBD Behaves Differently
CBD does not bind strongly at CB1, which is why it is not intoxicating. Its activity appears to be indirect and distributed: modulating how the receptor responds to other compounds, affecting endocannabinoid breakdown, and acting at receptor systems outside the endocannabinoid system entirely.
This is also why CBD research is harder to interpret than THC research. A compound with several modest effects across multiple systems is more difficult to characterise than one with a strong effect at a single receptor. See the science behind medical cannabis research.
Why Effects Vary So Much Between People
Endocannabinoid systems differ between individuals — in receptor density and distribution, in enzyme activity, and in baseline endocannabinoid levels. Genetic variation in the FAAH gene, for instance, affects how quickly anandamide is broken down.
Regular THC exposure also downregulates CB1 receptors, which is the mechanism behind tolerance, and receptor density recovers with abstinence.
The practical implication is that no laboratory measurement predicts individual response. A certificate of analysis tells you precisely what is in a product; the endocannabinoid system on the receiving end is not something a laboratory can measure. This is the core reason potency is not a prediction — covered in THC percentage explained.
Where the Research Actually Stands
The endocannabinoid system is well established as a physiological system, and its role in regulating the functions above is not seriously disputed.
What is less settled is the therapeutic picture. The hypothesis of “clinical endocannabinoid deficiency” — that some conditions reflect an underactive endocannabinoid system — is a plausible framework that remains under-evidenced. Much of what is claimed for cannabinoid therapy rests on preclinical work rather than controlled human trials.
Understanding the system explains mechanism. It does not, on its own, establish clinical effect. That distinction is worth holding onto when reading cannabis health claims, and it is the framing behind conditions most often studied in medical cannabis research.
For what the plant actually produces, see cannabinoids explained and terpenes and the entourage effect.